High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1258-1264

  Uçkay, Ilker ^a   Bernard, Louis ^a,b   Buzzi, Marta ^a   Harbarth, Stephan ^a   François, Patrice ^a   Huggler, Elzbieta ^a   Ferry, Tristan ^a,c   Schrenzel, Jacques ^a   Renzoni, C Adriana ^a   Vaudaux, Pierre ^a   Lew, Daniel P ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b CHU BRETONNEAU   (France)

^c CROIX ROUSSE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN; VANCOMYCIN;

EID: 84857186219     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05808-11     Document Type: Article

References (55)

1. Bae IG, et al. 2009. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J. Infect. Dis. 200: 1355-1366.
2. Bernard L, et al. 2004. Comparative analysis and validation of different assays for glycopeptide susceptibility among methicillin-resistant Staphylococcus aureus strains. J. Microbiol. Methods 57:231-239. (Pubitemid 38446868)
3. Chang FY, et al. 2003. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 82:333-339.
4. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40:373-383. (Pubitemid 17055592)
5. Clinical Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M07-A8, 8th ed. CLSI, Wayne, PA.
6. Clinical Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing, 19th informational supplement, M100-S19. CLSI, Wayne, PA.
7. de Kraker ME, Wolkewitz M, Davey PG, Grundmann H. 2011. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob. Agents Chemother. 55:1598-1605.
8. Deresinski S. 2007. Vancomycin and Staphylococcus aureus - an antibiotic enters obsolescence. Clin. Infect. Dis. 44:1543-1548. (Pubitemid 46871499)
9. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. 2000. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J. Clin. Microbiol. 38:1008-1015. (Pubitemid 30140551)
10. European Committee on Antimicrobial Susceptibility Testing. Glycopeptides: EUCASTclinicalMICbreakpoints 2009-09-29 (v 2.0). www.srga .org/eucastwt/mictab/MICglycopeptidesv2.html. EUCAST, Basel, Switzerland.
11. Falagas ME, Makris GC, Dimopoulos G, Matthaiou DK. 2008. Heteroresistance: a concern of increasing clinical significance? Clin. Microbiol. Infect. 14:101-104.
12. Ferry T, et al. 2010. Risk factors for treatment failure in orthopedic device-related methicillin-resistant Staphylococcus aureus infection. Eur. J. Clin. Microbiol. Infect. Dis. 29:171-180.
13. Fowler VG, Jr, et al. 1999. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J. Infect. Dis. 179: 1157-1161.
14. Francois P, et al. 2008. Methicillin-resistant Staphylococcus aureus, Geneva, Switzerland, 1993-2005. Emerg. Infect. Dis. 14:304-307. (Pubitemid 351213683)
15. Francois P, et al. 2005. Use of an automated multiple-locus, variablenumber tandem repeat-based method for rapid and high-throughput genotyping of Staphylococcus aureus isolates. J. Clin. Microbiol. 43:3346-3355. (Pubitemid 40981347)
16. Gould IM. 2007. The problem with glycopeptides. Int. J. Antimicrob. Agents 30:1-3. (Pubitemid 46876757)
17. Gould IM. 2008. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int. J. Antimicrob. Agents 31(Suppl. 2):1-9. (Pubitemid 351657677)
18. Gould IM, et al. 2011. Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits? Int. J. Antimicrob. Agents 37:202-209.
19. Harbarth S, et al. 2000. Effect of delayed infection control measures on a hospital outbreak of methicillin-resistant Staphylococcus aureus. J. Hosp. Infect. 46:43-49.
20. Harbarth S, et al. 2006. Evaluation of rapid screening and pre-emptive contact isolation for detecting and controlling methicillin-resistant Staphylococcus aureus in critical care: an interventional cohort study. Crit. Care 10:R25.
21. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166:2138-2144. (Pubitemid 44631403)
22. Hiramatsu K, et al. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673. (Pubitemid 28036828)
23. Horne KC, et al. 2009. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob. Agents Chemother. 53:3447-3452.
24. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99-139.
25. Hsu DI, et al. 2008. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents 32:378-385.
26. Khatib R, et al. 2011. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. 66:1594-1599.
27. Kullar R, Davis SL, Levine DP, Rybak MJ. 2011. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin. Infect. Dis. 52:975-981.
28. Liu C, Chambers HF. 2003. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47: 3040-3045. (Pubitemid 37229554)
29. Lodise TP, et al. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52:3315-3320.
30. Maclayton DO, Suda KJ, Coval KA, York CB, Garey KW. 2006. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin. Ther. 28:1208-1216. (Pubitemid 44374748)
31. Maor Y, et al. 2009. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis. 199:619-624.
32. Maor Y, et al. 2009. Molecular features of heterogeneous vancomycin-intermediate Staphylococcus aureus strains isolated from bacteremic patients. BMC Microbiol. 9:189.
33. Maor Y, et al. 2007. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J. Clin. Microbiol. 45:1511-1514. (Pubitemid 46762406)
34. Miyazaki M, et al. 2011. Vancomycin bactericidal activity as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 55:1819-1820.
35. Mohr JF, Murray BE. 2007. Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 44:1536-1542. (Pubitemid 46871498)
36. Moise PA, Sakoulas G, Forrest A, Schentag JJ. 2007. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 51:2582-2586. (Pubitemid 47047340)
37. Moise-Broder PA, et al. 2004. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38:1700-1705. (Pubitemid 38781661)
38. Musta AC, et al. 2009. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 47:1640-1644.
39. Oliveira DC, Tomasz A, De Lencastre H. 2002. Secrets of success of a human pathogen: molecular evolution of pandemic clones of meticillin-resistant Staphylococcus aureus. Lancet Infect. Dis. 2:180-189. (Pubitemid 34462453)
40. Patel N, et al. 2011. Vancomycin: we can't get there from here. Clin. Infect. Dis. 52:969-974.
41. Pitz AM, et al. 2011. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates. J. Clin. Microbiol. 49:269-274.
42. Prakash V, Lewis JS, Jorgensen JH. 2008. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob. Agents Chemother. 52:4528.
43. Renzoni A, et al. 2011. Whole genome sequencing and complete genetic analysis reveals novel pathways to glycopeptide resistance in Staphylococcus aureus. PLoS One 6:e21577.
44. Renzoni A, Kelley WL, Vaudaux P, Cheung AL, Lew DP. 2010. Exploring innate glycopeptide resistance mechanisms in Staphylococcus aureus. Trends Microbiol. 18:55-56.
45. Riederer K, et al. 2011. Detection of vancomycin-intermediately susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and agar screening methods. J. Clin. Microbiol.
46. Sakoulas G, et al. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402. (Pubitemid 38747480)
47. Tenover FC, Moellering RC, Jr. 2007. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44:1208-1215. (Pubitemid 46651246)
48. Uckay I, et al. 2008. Effect of screening for methicillin-resistant Staphylococcus aureus carriage by polymerase chain reaction on the duration of unnecessary preemptive contact isolation. Infect. Control Hosp. Epidemiol. 29:1077-1079.
49. van Hal SJ, Paterson DL. 2011. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55:405-410.
50. van Hal SJ, et al. 2011. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J. Clin. Microbiol. 49:1489-1494.
51. Vaudaux P, et al. 2010. Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 54:3861-3870.
52. Walsh TR, et al. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444. (Pubitemid 32606216)
53. Wootton M, et al. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403. (Pubitemid 32303403)
54. Wootton M, Walsh TR, MacGowan AP. 2005. Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3982-3983. (Pubitemid 41233067)
55. Zelenitsky S, Alkurdi N, Weber Z, Ariano R, Zhanel G. 2011. Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model. Antimicrob. Agents Chemother. 55:3627-3630.